Institution
Hebron University
Education•Hebron, Palestinian Territory•
About: Hebron University is a education organization based out in Hebron, Palestinian Territory. It is known for research contribution in the topics: Population & Cancer. The organization has 2714 authors who have published 4180 publications receiving 163736 citations.
Papers published on a yearly basis
Papers
More filters
••
University College London1, Hebron University2, Aarhus University Hospital3, University of Padua4, University of South Alabama5, Copenhagen University Hospital6, Semmelweis University7, University of Duisburg-Essen8, Centro Nacional de Investigaciones Cardiovasculares9, National and Kapodistrian University of Athens10, Duke University11, University of Birmingham12, John Radcliffe Hospital13, South African Medical Research Council14, St Thomas' Hospital15, Sapporo Medical University16, University of Miami17, University of Oldenburg18, Wayne State University19, National University of Singapore20, Cincinnati Children's Hospital Medical Center21, Spanish National Research Council22, Emory University23
TL;DR: An overview of the major topics discussed at this special meeting of leading pioneers in the field of cardioprotection to review and discuss the history of IPC, its evolution to IPost and RIC, myocardial reperfusion injury as a therapeutic target, and future targets and strategies for cardioprotsection is provided.
Abstract: To commemorate the auspicious occasion of the 30th anniversary of IPC, leading pioneers in the field of cardioprotection gathered in Barcelona in May 2016 to review and discuss the history of IPC, its evolution to IPost and RIC, myocardial reperfusion injury as a therapeutic target, and future targets and strategies for cardioprotection. This article provides an overview of the major topics discussed at this special meeting and underscores the huge importance and impact, the discovery of IPC has made in the field of cardiovascular research.
266 citations
••
Fox Chase Cancer Center1, Yale University2, University of Washington3, Curie Institute4, Cross Cancer Institute5, Duke University6, Hebron University7, Aix-Marseille University8, Bosch9, University of Texas Southwestern Medical Center10, Sarah Cannon Research Institute11, Bristol-Myers Squibb12, Johns Hopkins University13
TL;DR: In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab showed an improvement in o... as mentioned in this paper, and showed an improved lung cancer survival.
Abstract: PURPOSEImmunotherapy has revolutionized the treatment of advanced non–small-cell lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab showed an improvement in o...
266 citations
••
TL;DR: The ability of trastuzumab to inhibit HER2 cleavage may correlate with the clinical anticancer activity of the multifunctional HER2-targeting antibody.
264 citations
••
VU University Medical Center1, University of Genoa2, University of Graz3, Autonomous University of Barcelona4, Hebron University5, University College London6, National Institute for Health Research7, University of Oxford8, University of Siena9, Heidelberg University10, University Hospital of Basel11
TL;DR: This large multicentre study points to the complementary predictive value of atrophy and lesion volumes for predicting long term disability in MS.
Abstract: Objective To determine whether brain atrophy and lesion volumes predict subsequent 10 year clinical evolution in multiple sclerosis (MS). Design From eight MAGNIMS (MAGNetic resonance Imaging in MS) centres, we retrospectively included 261 MS patients with MR imaging at baseline and after 1–2 years, and Expanded Disability Status Scale (EDSS) scoring at baseline and after 10 years. Annualised whole brain atrophy, central brain atrophy rates and T2 lesion volumes were calculated. Patients were categorised by baseline diagnosis as primary progressive MS (n=77), clinically isolated syndromes (n=18), relapsing–remitting MS (n=97) and secondary progressive MS (n=69). Relapse onset patients were classified as minimally impaired (EDSS=0–3.5, n=111) or moderately impaired (EDSS=4–6, n=55) according to their baseline disability (and regardless of disease type). Linear regression models tested whether whole brain and central atrophy, lesion volumes at baseline, follow-up and lesion volume change predicted 10 year EDSS and MS Severity Scale scores. Results In the whole patient group, whole brain and central atrophy predicted EDSS at 10 years, corrected for imaging protocol, baseline EDSS and disease modifying treatment. The combined model with central atrophy and lesion volume change as MRI predictors predicted 10 year EDSS with R 2 =0.74 in the whole group and R 2 =0.72 in the relapse onset group. In subgroups, central atrophy was predictive in the minimally impaired relapse onset patients (R 2 =0.68), lesion volumes in moderately impaired relapse onset patients (R 2 =0.21) and whole brain atrophy in primary progressive MS (R 2 =0.34). Conclusions This large multicentre study points to the complementary predictive value of atrophy and lesion volumes for predicting long term disability in MS.
263 citations
••
St Bartholomew's Hospital1, Hebron University2, Aarhus University Hospital3, University College London4, University of South Alabama5, Duke University6, South African Medical Research Council7, Sheba Medical Center8, The Texas Heart Institute9, Claude Bernard University Lyon 110, University of Angers11, University of Giessen12, Utrecht University13, Emory University14, Semmelweis University15
TL;DR: The current state of ischaemic conditioning in both the experimental and clinical settings is critically analysed, recommendations for improving its translation into the clinical setting are provided, and novel therapeutic targets and new treatment strategies for reducing acute myocardial ischaemia/reperfusion injury are highlighted.
Abstract: Ischaemic heart disease and the heart failure that often results, remain the leading causes of death and disability in Europe and worldwide. As such, in order to prevent heart failure and improve clinical outcomes in patients presenting with an acute ST-segment elevation myocardial infarction and patients undergoing coronary artery bypass graft surgery, novel therapies are required to protect the heart against the detrimental effects of acute ischaemia/reperfusion injury (IRI). During the last three decades, a wide variety of ischaemic conditioning strategies and pharmacological treatments have been tested in the clinic-however, their translation from experimental to clinical studies for improving patient outcomes has been both challenging and disappointing. Therefore, in this Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart, we critically analyse the current state of ischaemic conditioning in both the experimental and clinical settings, provide recommendations for improving its translation into the clinical setting, and highlight novel therapeutic targets and new treatment strategies for reducing acute myocardial IRI.
261 citations
Authors
Showing all 2723 results
Name | H-index | Papers | Citations |
---|---|---|---|
José Baselga | 156 | 707 | 122498 |
M. I. Martínez | 134 | 1251 | 79885 |
Josep Tabernero | 111 | 803 | 68982 |
Jordi Rello | 103 | 694 | 35994 |
Xavier Montalban | 95 | 762 | 52842 |
James M. Downey | 91 | 381 | 29506 |
Enriqueta Felip | 83 | 622 | 53364 |
Joaquim Bellmunt | 82 | 660 | 41472 |
Joan Montaner | 80 | 489 | 22413 |
Marc Miravitlles | 76 | 651 | 25671 |
David H. Salat | 75 | 241 | 36779 |
Eduard Gratacós | 75 | 531 | 20178 |
Alex Rovira | 74 | 356 | 19586 |
Ramon Bataller | 72 | 283 | 19316 |
Maria Buti | 71 | 493 | 26596 |